The early risk of thrombolytic therapy for acute myocardial infarction: Incidence, mechanisms and possible prevention

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 5, Issue 2, 1998, Pages 103-108

  Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

beta blockade; myocardial infarction; rupture; stroke; thrombolytic therapy

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; MAGNESIUM; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRAIN HEMORRHAGE; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HEART RUPTURE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPERFUSION INJURY;

BLOOD PRESSURE; CEREBRAL HEMORRHAGE; HEART RUPTURE, POST-INFARCTION; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 0031660687     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182679800500206     Document Type: Article

References (24)

1. Verstraete M. Thrombolytic therapy in acute myocardial infarction Circulation 1990; 82 (suppl II):II96–II109.
2. Verheugt FWA, Meijer A, Lagrand WK, Van Eenige MJ. Reocclusion, the flipside of coronary thrombolysis J Am Coll Cardiol 1996; 27: 766–773.
3. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-1 trial Circulation 1995; 92: 2811–2818.
4. Fibrinolytic Therapy Trialist's Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trial of more than 1,000 patients Lancet 1994; 343: 311–322.
5. Bosch X, Theroux P, Waters DD, Pelletier GB, Roy D. Early postinfarct ischemia: Clinical, angiographic, and prognostic significance Circulation 1987; 75: 988–995.
6. Verstraete M, Arnold AER, Bleifeld WH, Brower RW, Collen D, De Bono DP, et al Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rate Am J Cardiol 1987; 60: 231–237.
7. Boissel JP, Castaigne A, Mercier C, Lion L, Leizorovicz Ventricular fibrillation following administration of thrombolytic therapy: The EMIP experience Eur Heart J 1996; 17: 213–221.
8. Maynard C, Weaver WD, Lambrew C, Bowlby LJ, Rogers WJ, Rubison RM. Factors influencing time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction) Am J Cardiol 1995; 76: 548–552.
9. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, De Jaegere P, Van Domburg R, et al Individual risk assessment for intracranial haemorrhage during thrombolytic therapy Lancet 1993; 342: 1523–1528.
10. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 1993; 329: 673–682.
11. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction N Engl J Med 1993; 329: 1615–1622.
12. Honan MB, Farrell PE, Reimer KA, Califf RM, Mark DB, Pryor DB, et al Cardiac rupture, mortality and the timing of thrombolytic therapy: A *meta-analysis J Am Coll Cardiol 1990; 16: 359–367.
13. Becker RC, Charlesworth A, Wilcox RG, Hampton Jr., Skene A, Gore JM. Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the Late Assessment of Thrombolytic therapy (LATE) study J Am Coll Cardiol 1995; 25: 1063–1068.
14. Wall RC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, et al Intravenous fluosol in the treatment of acute myocardial infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial Circulation 1994; 90: 114–120.
15. Collaborative Organisation for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction Circulation 1997; 96: 192–201.
16. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) Lancet 1992; 339: 1553–1558.
17. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction Lancet 1995; 345: 669–685.
18. Baxter GF, Sumuray MS, Walker JM. Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studies Lancet 1996; 348: 1424–1426.
19. Roberts R, Rogers WJ, Mueller H, Lambrew CT, Diver DJ, Smith HC, et al Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial infarction (TIMI) II-B study Circulation 1991; 83: 422–437.
20. Barron HV, Rundle AC, Gore JM, Gurwitz J. Reduction of intracranial hemorrhage associated with immediate beta-blocker therapy in patients with acute myocardial infarction treated with tissue plasminogen activator [abstract] J Am Coll Cardiol 1998; 31 (suppl A):371 A.
21. Gruppo per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-weeks mortality and ventricular function after acute myocardial infarction Lancet 1994; 343: 1115–1122.
22. Swedberg K, Held P, Kjekhus J, Rasmussen K, Ryden L, Wedel H. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study-2 (CONSENSUS-2) N Engl J Med 1992; 327: 678–684.
23. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Mechanism for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1 Lancet 1988; i: 921–923.
24. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction Lancet 1990; 336: 65–71.